CLOs on the Move

Boone Drug At New Market

www.boonedrug.com

 
Boone Drug and Healthcare at Deerfield offers a broad range of retail pharmacy, home medical equipment, prosthetic and orthotic goods, home respiratory care, post mastectomy fitters services, enteral therapy services to fill the medical and convalescent
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Flexicare

Flexicare is a privately owned, leading manufacturer and supplier of medical devices with over 40 years of experience in the healthcare sector. With over 40 years of experience in the design, development and manufacture of medical devices, Flexicare ha...

Fresh Tracks Therapeutics

Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company focused on transforming patient lives through the development of innovative and ground-breaking prescription therapeutics.

Anderson Packaging

Anderson Packaging is a Rockford, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longeveron

Longeveron is a clinical stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. Their lead investigational product is Lomecel B™, which is derived from culture-expanded medicinal signaling cells ...

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.